Sanara MedTech stock gains after shareholders approve merger

Published on 10/05/2026 at 20:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanara MedTech stock was trading at USD 35.02 on October 5, 2026, up 0.50 percent on Nasdaq. Q2 revenue reached USD 28.14 million against USD 28.95 million expected.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech stock (ISIN US79957L1008) was trading at USD 35.02 on Nasdaq at 2:28 p.m. ET on October 5, 2026, up 0.50 percent from the previous close. The latest corporate development is shareholder approval of the proposed MiMedx merger at Sanara's September 30 special meeting, as StockTitan reported in the related filing.

Merger approval clears a key vote

Proposal 1 received 6,372,989 votes for, 1,944 against and 36,494 abstentions. Proposal 2, covering merger-related executive compensation, received 5,841,470 votes for, 75,247 against and 494,710 abstentions, according to StockTitan.

The regulatory timetable now provides the next concrete checkpoint. MiMedx and Sanara refiled their HSR notification on September 15, starting a new 30-calendar-day waiting period that is scheduled to expire at 11:59 p.m. ET on October 15, 2026, unless extended or ended early, the filing said through StockTitan. The merger still depends on the remaining conditions in the agreement.

Q2 revenue grew but missed estimates

Sanara's second-quarter 2026 revenue was USD 28.14 million, below the USD 28.95 million consensus estimate by USD 0.81 million, or 2.8 percent. The quarterly EPS loss was USD 0.05 compared with a consensus loss of USD 0.02, a USD 0.03 miss, according to MarketBeat. The contrast matters for investors because merger progress is developing alongside an operating quarter that fell short of expectations.

MarketBeat also reported an average Reduce rating from five brokerages, consisting of four holds and one sell, with a consensus 12-month target of USD 35.00. That target sits USD 0.02 below the October 5 intraday price, making the merger timetable more important than a broad analyst upside case.

SMTI trades near its yearly high

At USD 35.02, SMTI was USD 0.32 below its 52-week high of USD 35.34 on October 5, 2026. The 52-week low was USD 16.05, while the market capitalization stood at USD 322.0 million, giving the stock a wide 52-week span despite its position near the upper end.

The share price was trading between USD 34.74 and USD 35.06 during the October 5 session. The next material date for the merger is October 15, when the HSR waiting period is scheduled to expire under the conditions described in the filing.